乳房生検装置市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、施術別、用途別、エンドユーザー別、地域別、競合別セグメント、2019-2029年

乳房生検装置の世界市場規模は2023年に8億4,000万米ドルとなり、2029年までの予測期間のCAGRは6.69%で着実な成長が予測されています。

乳房生検装置として知られる専門医療機器によって促進される乳房生検技術は、乳がんの診断と管理において重要な役割を果たしています。乳房生検とは、異常や病気の兆候を発見するために、乳房から組織や体液を摘出し、通常顕微鏡下で検査する外科的処置です。摘出された組織は綿密に分析され、がん細胞が含まれているかどうかが判定され、患者の正確な診断とその後の治療計画に役立ちます。生検は、がんの存在を確認し、ヘルスケアプロバイダーが個々の症例に合わせた効果的な治療戦略を立てるための指針として不可欠です。

乳房生検は、患者の特定の状況や要求に応じて様々な手法が採用されます。これらの技術には、皮膚生検、剃毛生検、細針吸引、切開生検、摘出生検コア、真空補助生検などがあります。それぞれの手技には固有の目的があり、疑われる病変の大きさや位置、組織への接近性、医療従事者の診断要件などの要因に基づいて利用されます。これらの手技は、乳がんの診断経路における重要なステップであり、ヘルスケア専門家が病態の正確な評価と診断のために組織サンプルを得ることを可能にします。

世界の乳房生検装置市場の成長促進要因は、世界の乳がん罹患率の増加です。乳がんは世界的に女性の間で最も罹患率の高いがんの1つであり、毎年数百万人の症例が新たに診断されています。乳がんとその危険因子に対する認識が高まり続けるにつれ、乳がん検診プログラムと診断サービスに対する需要もそれに対応して増加しています。乳房生検装置とその関連技術は、一般的に治療成績がより良好な早期段階での乳がんの正確な発見と診断を促進するため、ニーズが高まっています。

乳房生検装置市場は、低侵襲性乳房生検技術が広く受け入れられていることから成長を遂げています。低侵襲手技には、患者の不快感の軽減、回復時間の短縮、合併症リスクの低減など、従来の手術法に比べていくつかの利点があります。このような利点から、ヘルスケアプロバイダーによる低侵襲生検技術の採用が増加し、それに伴い、これらの手技を容易にするために設計された高度な乳房生検装置に対する需要が急増しています。ヘルスケアシステムが患者中心のケアと低侵襲介入を優先し続ける中、乳房生検装置の市場は今後さらに拡大すると予想されます。

主な市場促進要因

乳がん罹患率の上昇

意識の高まりと早期発見

低侵襲手術に対する需要の高まり

主な市場課題

コスト制約

償還の問題

主な市場動向

3Dマンモグラフィの統合

人工知能（AI）の支援

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（生検針、ガイダンスシステム、生検台、位置測定ワイヤー、アッセイキット、液体生検器具、その他）
  • 施術別（針生検、開胸手術による乳房生検、液体乳房生検）
  • 用途別（早期がんスクリーニング、治療法の選択、治療モニタリング、再発モニタリング）
  • エンドユーザー別（病院、外科センター、乳がんケアセンター、画像診断クリニック、診断センター）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2023）
• 市場マップ
• タイプ別
• 施術別
• 用途別
• エンドユーザー別
• 地域別

第6章 北米の乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 施術別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 施術別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 施術別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 施術別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの乳房生検装置市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 施術別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の乳房生検装置市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Hologic Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Argon Medical Devices, Inc.
• Guardant Health, Inc.
• Merit Medical Systems, Inc.
• Neogenomics Laboratories, Inc.
• Sysmex Inostics, Inc.
• Sterylab S.R.L.
• Bio-Rad Laboratories Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Breast Biopsy Devices Market was valued at USD 0.84 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.69% through 2029. Breast biopsy techniques, facilitated by specialized medical instruments known as breast biopsy devices, play a critical role in the diagnosis and management of breast cancer. A breast biopsy is a surgical procedure that involves the removal of tissue or fluid from the breast for examination, typically under a microscope, to detect any abnormalities or signs of illness. The excised tissue is meticulously analyzed to determine whether it contains cancerous cells, aiding in the accurate diagnosis and subsequent treatment planning for the patient. Biopsy procedures are essential in confirming the presence of cancer and guiding healthcare providers in formulating effective treatment strategies tailored to each individual case.

Various breast biopsy techniques are employed depending on the specific circumstances and requirements of the patient. These techniques include skin biopsy, shave biopsy, fine needle aspiration, incision biopsy, excision biopsy core, and vacuum-assisted biopsy, among others. Each technique serves a unique purpose and may be utilized based on factors such as the size and location of the suspected lesion, the accessibility of the tissue, and the diagnostic requirements of the healthcare provider. These procedures are crucial steps in the diagnostic pathway for breast cancer, enabling healthcare professionals to obtain tissue samples for accurate assessment and diagnosis of the condition.

The primary driver of growth in the global Breast Biopsy Device Market is the increasing incidence of breast cancer worldwide. Breast cancer is one of the most prevalent forms of cancer among women globally, with millions of new cases diagnosed each year. As awareness of breast cancer and its risk factors continues to grow, there has been a corresponding rise in the demand for breast cancer screening programs and diagnostic services. There is a greater need for breast biopsy devices and related technologies to facilitate the accurate detection and diagnosis of breast cancer at early stages when treatment outcomes are typically more favorable.

The market for breast biopsy devices is witnessing growth due to the widespread acceptance of minimally invasive breast biopsy techniques. Minimally invasive procedures offer several advantages over traditional surgical methods, including reduced patient discomfort, shorter recovery times, and decreased risk of complications. These benefits have led to increased adoption of minimally invasive biopsy techniques by healthcare providers and a corresponding surge in demand for advanced breast biopsy devices designed to facilitate these procedures. As healthcare systems continue to prioritize patient-centered care and minimally invasive interventions, the market for breast biopsy devices is expected to expand further in the coming years.

Key Market Drivers

Rising Incidence of Breast Cancer

As the incidence of breast cancer continues to rise, there is a growing need for accurate and timely diagnostic procedures. Breast biopsy is a critical step in confirming the presence of breast cancer and determining its type and stage. This increased demand for breast cancer diagnosis drives the utilization of breast biopsy devices. Public health awareness campaigns and screening programs emphasize the importance of early detection in improving breast cancer outcomes. Mammography and other screening methods often lead to the identification of suspicious breast lesions, which then require biopsy for further evaluation. The rising incidence of breast cancer underscores the need for more frequent screenings and, subsequently, more breast biopsies. Accurate diagnosis is crucial for developing an effective treatment plan. As more cases of breast cancer are diagnosed, the demand for precise and comprehensive information about the tumor, such as its type, size, and genetic characteristics, increases.

Breast biopsy devices play a pivotal role in obtaining the tissue samples needed for such detailed analysis. Patients diagnosed with breast cancer often prefer less invasive diagnostic procedures. This preference is particularly strong when dealing with the early stages of cancer. Advances in breast biopsy devices have led to the development of minimally invasive techniques, such as core needle biopsies, which are less painful and have shorter recovery times compared to traditional surgical biopsies. This aligns with patient preferences and further drives the adoption of breast biopsy devices. The rising incidence of breast cancer is not limited to developed countries but is also prevalent in emerging economies. As healthcare infrastructure improves and awareness increases in these regions, there is a growing market for breast biopsy devices. This expansion contributes to the global growth of the market. The growing prevalence of breast cancer has prompted increased research and development investments in the field of breast biopsy devices. Manufacturers are motivated to innovate and develop new technologies that can enhance the accuracy and efficiency of breast biopsy procedures, further fueling market growth.

Growing Awareness and Early Detection

Growing awareness campaigns, education initiatives, and public health efforts have successfully encouraged women to undergo regular breast cancer screenings. These campaigns emphasize the importance of early detection, leading to an increased number of screenings and mammography tests. When abnormalities or suspicious lesions are detected through these screenings, it often necessitates further evaluation through breast biopsy procedures. The heightened awareness and emphasis on early detection result in a greater demand for breast biopsy devices. Early detection of breast cancer significantly improves treatment outcomes and survival rates. Patients diagnosed at an early stage typically require less aggressive treatments and have a higher chance of successful recovery. Healthcare providers, therefore, prioritize timely diagnosis through biopsy to ensure that patients receive appropriate and timely treatment. This drives the demand for efficient and accurate breast biopsy devices.

Many countries have established breast cancer screening programs and guidelines that recommend regular screenings for specific age groups or risk categories. These programs create a consistent and continuous demand for breast biopsy procedures, especially when screening identifies suspicious findings. This demand sustains the market for breast biopsy devices. Not only are patients becoming more aware of the importance of breast cancer screening, but physicians are also increasingly vigilant in recommending screenings for their patients. Physician recommendations play a crucial role in patient compliance with screening guidelines. When abnormal findings occur, physicians rely on breast biopsy devices to confirm or rule out cancer. The emphasis on early detection has driven innovations in breast biopsy device technology. Manufacturers invest in research and development to create devices that are more accurate, less invasive, and quicker, aligning with the goals of early detection. These advancements not only improve patient experiences but also make breast biopsy procedures more accessible, encouraging more individuals to undergo the necessary tests.

Growing demand for Minimally Invasive Procedures

Patients increasingly prefer minimally invasive procedures over traditional surgical approaches due to their many benefits, such as reduced pain, shorter recovery times, and smaller scars. As patient preferences evolve, there is a higher demand for breast biopsy devices that enable minimally invasive techniques. Minimally invasive breast biopsy procedures are associated with lower discomfort and pain during and after the procedure. This improved patient experience encourages more individuals to undergo breast biopsy, leading to a higher overall demand for biopsy devices. Patients are more likely to comply with recommended breast cancer screenings and diagnostic procedures when they know that minimally invasive options are available. This increased compliance leads to earlier detection and diagnosis, driving the utilization of breast biopsy devices. Minimally invasive procedures typically result in shorter hospital stays and reduced post-operative care requirements, leading to cost savings for healthcare systems and patients.

As healthcare stakeholders seek cost-effective solutions, minimally invasive breast biopsy procedures become an attractive option, contributing to market growth. Manufacturers are continually developing and improving minimally invasive breast biopsy devices, incorporating advanced technologies such as ultrasound or stereotactic guidance. These innovations enhance the accuracy and precision of biopsy procedures, making them more appealing to both healthcare providers and patients. Minimally invasive breast biopsy procedures allow patients to return to their normal daily activities more quickly than traditional surgical biopsies. This feature is particularly valuable for individuals with busy lives or those who want to minimize disruptions caused by medical procedures, further boosting the demand for minimally invasive biopsy devices.

Key Market Challenges

Cost Constraints

High costs associated with breast biopsy procedures and devices can limit access to these critical diagnostic services, particularly for uninsured or underinsured patients. When the cost of a biopsy is prohibitive, individuals may delay or forgo necessary screenings, leading to missed diagnoses and later-stage cancer detection. Healthcare facilities and providers may hesitate to invest in expensive breast biopsy devices, especially in regions with budget constraints. This reluctance can slow the adoption of advanced biopsy technologies, keeping healthcare systems reliant on older, potentially less effective methods. Expensive biopsy devices and procedures can strain healthcare budgets and resources. This financial burden may divert resources away from other essential healthcare services, leading to a compromise in overall healthcare quality.

Cost constraints can exacerbate healthcare disparities, with patients in lower-income brackets or underserved regions facing greater challenges in accessing breast biopsy services. This can lead to disparities in breast cancer outcomes, with disadvantaged populations experiencing delayed diagnoses and poorer survival rates. High biopsy costs can discourage healthcare providers from participating in breast cancer screening programs, as they may be concerned about the financial implications of follow-up biopsies. This, in turn, can reduce the effectiveness of population-wide screening efforts. Patients who cannot afford timely breast biopsies may experience delayed diagnosis and treatment initiation. Delayed diagnosis can result in cancer progression, necessitating more extensive and expensive treatments, ultimately increasing the overall cost of care.

Reimbursement Issues

Inconsistent or inadequate reimbursement policies can result in higher out-of-pocket costs for patients undergoing breast biopsy procedures. When patients are required to bear a significant financial burden, they may be less likely to opt for these procedures, which can lead to delayed diagnoses and treatment. Healthcare providers and facilities may be hesitant to offer breast biopsy services if reimbursement rates do not cover the cost of the procedure. This reluctance can reduce the availability of biopsy services and limit patient access, particularly in underserved areas. Inefficient or delayed reimbursement processes can strain the finances of healthcare practices and facilities.

When payments are delayed or insufficient, it can create financial instability, which may, in turn, affect their ability to invest in advanced biopsy devices or maintain high-quality care. Inadequate reimbursement for newer, more advanced breast biopsy devices may discourage healthcare facilities from adopting these technologies. Providers may opt for lower-cost, older biopsy methods that are more likely to be reimbursed at acceptable rates. Stricter reimbursement requirements and delays in obtaining reimbursement approvals can create barriers for manufacturers trying to introduce new breast biopsy devices to the market. This can slow down the innovation and development of advanced technologies. Reimbursement policies can vary significantly by region or country. This can result in regional disparities in access to breast biopsy procedures, with patients in certain areas having better access to advanced technologies and reimbursement rates than others.

Key Market Trends

3D Mammography Integration

3D mammography provides clearer and more detailed images of breast tissue, allowing healthcare providers to better identify and localize suspicious lesions. This improved precision reduces the need for multiple biopsy attempts, streamlining the diagnostic process. The combination of 3D mammography with breast biopsy procedures increases the accuracy of lesion targeting. This accuracy minimizes the chances of missing a malignancy or obtaining inadequate tissue samples, leading to more reliable biopsy results and reduced false negatives. Enhanced accuracy means that biopsy procedures can be quicker and require fewer tissue samples, resulting in reduced patient discomfort and anxiety.

Patients are more likely to comply with recommended breast biopsy procedures when they know the process is efficient and minimally invasive. Radiologists and healthcare providers can have greater confidence in the diagnostic results when 3D mammography is integrated into biopsy procedures. This confidence is vital for effective treatment planning and patient counseling. By improving lesion localization and accuracy, 3D mammography integration can reduce the need for additional diagnostic procedures or surgeries. This not only saves time and resources but also reduces patient stress and inconvenience. Healthcare facilities benefit from more efficient workflows when using integrated 3D mammography systems. Quicker procedures and more accurate results can lead to increased patient throughput and improved utilization of healthcare resources.

Artificial Intelligence (AI) Assistance

AI algorithms can analyze mammograms and other imaging data with incredible speed and accuracy. By assisting radiologists and clinicians in interpreting images and identifying suspicious lesions, AI can significantly enhance the accuracy of breast cancer diagnosis. This increased accuracy is a major driver for the adoption of AI-assisted breast biopsy devices. AI can automate repetitive tasks, such as lesion detection and segmentation, reducing the workload on healthcare professionals. This leads to more efficient workflow processes, allowing providers to serve more patients and potentially reducing wait times for biopsies. The resulting workflow efficiency can be a compelling factor for healthcare facilities considering the adoption of AI-powered breast biopsy devices. AI algorithms can help reduce both false positives and false negatives in breast cancer diagnosis.

Fewer false positives mean fewer unnecessary biopsies, lowering the cost of healthcare, while fewer false negatives enhance patient safety by ensuring that cancers are not missed during diagnosis. AI can analyze patient data and pathology results to help tailor treatment plans for individuals based on their unique characteristics. This trend is driving the development of breast biopsy devices that can collect tissue samples suitable for genomic analysis. Personalized medicine is considered the future of cancer treatment, and AI plays a pivotal role in making it a reality. AI-assisted breast biopsy devices can expedite the diagnostic process. Automated image analysis and data interpretation can reduce the time it takes to make a diagnosis, allowing patients to receive timely treatment when needed. This is particularly critical in cases where rapid intervention is essential. AI-powered breast biopsy devices can facilitate telemedicine and remote consultations. Radiologists and specialists can review images and provide guidance from remote locations, expanding access to expert care and reducing geographical barriers to diagnosis and treatment.

Segmental Insights

Type Insights

Based on Type, the biopsy needles is anticipated to witness rapid growth throughout the forecast period in Global Breast Biopsy Devices Market. Biopsy needles must accurately target and extract tissue samples from breast lesions. Needles that can consistently achieve high levels of accuracy and precision in obtaining tissue samples contribute to the reliability of biopsy procedures. Healthcare providers and patients alike seek needles that minimize the risk of sampling errors and improve diagnostic accuracy. The demand for minimally invasive breast biopsy procedures, which are less painful and result in shorter recovery times, has been steadily increasing. Biopsy needles that facilitate these less invasive techniques, such as core needle biopsy or vacuum-assisted biopsy, are driving market growth. Patients often prefer these methods, which can lead to higher utilization of breast biopsy services. Biopsy needles that prioritize patient comfort and safety are well-received in the market. Design features such as smaller gauge sizes, smoother insertion, and reduced tissue trauma can lead to a better patient experience.

Needles that enable accurate lesion localization and targeting under imaging guidance enhance the efficiency of breast biopsy procedures, reducing the chances of sampling errors and the need for additional interventions. Continuous innovations in biopsy needle design, including advancements in needle materials and configurations, can lead to improved performance and diagnostic accuracy. Manufacturers invest in research and development to create needles that optimize tissue retrieval while minimizing patient discomfort. Biopsy needles that incorporate automation, such as automated sample collection or specimen retrieval, can enhance the efficiency of the biopsy procedure. Automation reduces the time required for each procedure, allowing healthcare providers to serve more patients and potentially lower healthcare costs.

Procedure Insights

Based on Procedure, the Liquid Breast Biopsy segment has been the dominant force in the Global Breast Biopsy Devices Market. Liquid breast biopsy offers a non-invasive alternative to traditional tissue biopsy procedures. Instead of extracting tissue samples through a needle or surgical biopsy, liquid biopsies detect cancer-related biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), in a patient's blood or other bodily fluids. This non-invasive approach can encourage more individuals to undergo breast cancer screening, potentially increasing the demand for biopsy services. Liquid biopsy techniques can detect breast cancer at an earlier stage, often before the formation of palpable tumors. Early detection is critical for improved treatment outcomes and reduced healthcare costs associated with advanced-stage cancer treatment. The ability to detect cancer markers in blood samples can lead to more timely interventions and lower morbidity rates.

Regional Insights

Based on region, North America emerged as the dominating region in the Global Breast Biopsy Devices Market in 2023. This is primarily due to North America boasts a highly advanced healthcare infrastructure, with state-of-the-art medical facilities, research institutions, and skilled healthcare professionals. This infrastructure supports the adoption of the latest breast biopsy devices and technologies. North America has a relatively high incidence of breast cancer, which drives the demand for breast biopsy procedures and devices. The awareness of breast cancer screening and early detection is strong in the region, contributing to a steady market demand. The United States and Canada are home to many leading medical device manufacturers and pharmaceutical companies. These entities invest heavily in research and development, leading to the creation of cutting-edge breast biopsy devices and technologies that are then introduced to the global market.

Key Market Players

Hologic Inc.

Danaher Corporation

Becton, Dickinson and Company

Argon Medical Devices, Inc.

Guardant Health, Inc.

Merit Medical Systems, Inc.

Neogenomics Laboratories, Inc.

Sysmex Inostics, Inc.

Sterylab S.R.L.

Bio-Rad Laboratories Inc.

Report Scope:

In this report, the Global Breast Biopsy Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Biopsy Devices Market, By Type:

Biopsy Needles Guidance Systems Biopsy Tables Localization Wires Assay Kits Liquid Biopsy Instruments Others

Breast Biopsy Devices Market, By Procedure:

Needle Breast Biopsy Open Surgical Breast Biopsy Liquid Breast Biopsy

Breast Biopsy Devices Market, By Application:

Early Cancer Screening Therapy Selection Treatment Monitoring Recurrence Monitoring

Breast Biopsy Devices Market, By End User:

Hospitals & Surgical Centers Breast Care Centers Imaging Clinics & Diagnostic Centers

Breast Biopsy Devices Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Biopsy Devices Market.

Available Customizations:

Global Breast Biopsy Devices Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Biopsy Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 5.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 5.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 5.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.6. By Company (2023)
• 5.3. Market Map
• 5.3.1 By Type
• 5.3.2 By Procedure
• 5.3.3 By Application
• 5.3.4 By End User
• 5.3.5 By Region

6. North America Breast Biopsy Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 6.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 6.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 6.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Biopsy Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Breast Biopsy Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Breast Biopsy Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Breast Biopsy Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 7.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 7.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 7.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Breast Biopsy Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Breast Biopsy Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Breast Biopsy Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Breast Biopsy Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Breast Biopsy Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Breast Biopsy Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 8.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 8.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 8.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Breast Biopsy Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Breast Biopsy Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Breast Biopsy Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Breast Biopsy Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Breast Biopsy Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Breast Biopsy Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 9.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 9.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 9.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Breast Biopsy Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Breast Biopsy Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Breast Biopsy Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Breast Biopsy Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others)
  • 10.2.2. By Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy)
  • 10.2.3. By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring)
  • 10.2.4. By End User (Hospitals & Surgical Centers, Breast Care Centers, Imaging Clinics & Diagnostic Centers)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Breast Biopsy Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Breast Biopsy Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Breast Biopsy Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Breast Biopsy Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1 Hologic Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Becton, Dickinson and Company
• 15.4. Argon Medical Devices, Inc.
• 15.5. Guardant Health, Inc.
• 15.6. Merit Medical Systems, Inc.
• 15.7. Neogenomics Laboratories, Inc.
• 15.8. Sysmex Inostics, Inc.
• 15.9. Sterylab S.R.L.
• 15.10. Bio-Rad Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer